1/1
PARV4 prevalence, phylogeny, immunology and coinfection with HIV, HBV and HCV in a multicentre African cohort
Version 3 2017-03-08, 11:28
Version 2 2017-03-01, 16:13
Version 1 2017-03-01, 14:25
dataset
posted on 2017-03-08, 11:28 authored by Colin Sharp, William Gregory, Louise Hattingh, Amna Malik, Emily Adland, Samantha Daniels, Jonathan Carlson, Susan Wareing, Martin Hadley, Anthony Ogwu, Roger Shapiro, Lynn Riddell, Fabian Chen, Thumbi Ndung'u, Philip Goulder, Paul Klenerman, Peter Simmonds, Pieter Jooste, Philippa MatthewsPhilippa MatthewsThis file contains supporting metadata for a study of human parvovirus 4 ('PARV4') in southern Africa. We compiled data from three centres (Kimberley and Durban in South Africa, and Gaborone in Botswana), by recruiting adults and children with and without HIV infection (n=695). We sought evidence of previous or current PARV4 infection, using IgG and PCR respectively, and screened for coinfection with HBV and HCV.
We have uploaded the following files (xls and csv format):
(i) The entire cohort descriptors;
(ii) PCR primers that we used to screen plasma pools for HCV and PARV4;
(iii) Panel of overlapping peptides (OLPs) spanning the PARV4 proteome used to screen PBMCs using IFN-gamma ELISpot assays;
(iv) The results of screening 14 PARV4 IgG-positive subjects using this ELISpot approach.
Ethics approval for this study was granted by the University of KwaZulu-Natal Review Board, Oxford Research Ethics Committee, Massachusetts General Hospital Review Board, Harvard School of Public Health, Botswana Ministry of Health, Ethics Committee of the University of the Free State, and by site-specific research and development committees in the UK.
